Compile Data Set for Download or QSAR
maximum 50k data
Found 466 of ec50 data for polymerid = 50000925,50006087
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509719(US11364246, Example 35.24 | US20200361871A1, Examp...)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509689(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  10nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509689(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509772(US11364246, Example 92.2 | US20200361871A1, Exampl...)
Affinity DataEC50:  10nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509773(US20200361871A1, Example 92.2)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509719(US11364246, Example 35.24 | US20200361871A1, Examp...)
Affinity DataEC50:  10nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509692(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509692(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509778(US11364246, Example 93.5 | US20200361871A1, Exampl...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509778(US11364246, Example 93.5 | US20200361871A1, Exampl...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509722(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509758(N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-5-(tr...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509758(N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-5-(tr...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509722(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509756(4-[[2-(4-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509756(4-[[2-(4-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509763(N-(4-Fluoro-1-bicyclo[2.1.1]hexanyl)-4-[[2-(5-fluo...)
Affinity DataEC50:  40nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509594(US11364246, Example 3.14b | US20200361871A1, Examp...)
Affinity DataEC50:  40nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509763(N-(4-Fluoro-1-bicyclo[2.1.1]hexanyl)-4-[[2-(5-fluo...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509594(US11364246, Example 3.14b | US20200361871A1, Examp...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509762(N-(1,1-Dimethylprop-2-ynyl)-4-[[2-(5-fluoro-2-hydr...)
Affinity DataEC50:  40nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509762(N-(1,1-Dimethylprop-2-ynyl)-4-[[2-(5-fluoro-2-hydr...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509775(US11364246, Example 93.2 | US20200361871A1, Exampl...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509775(US11364246, Example 93.2 | US20200361871A1, Exampl...)
Affinity DataEC50:  40nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509774(US11364246, Example 93.1 | US20200361871A1, Exampl...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509774(US11364246, Example 93.1 | US20200361871A1, Exampl...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509757(N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-4-(tr...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509730(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509724(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509649(US11364246, Example 7.15 | US20200361871A1, Exampl...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509730(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509757(N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-4-(tr...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509724(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509649(US11364246, Example 7.15 | US20200361871A1, Exampl...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509226(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  60nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509776(US11364246, Example 93.3 | US20200361871A1, Exampl...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509725(N-(4-tert-Butylcyclohexyl)-4-[[2-(5-chloro-2-hydro...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509776(US11364246, Example 93.3 | US20200361871A1, Exampl...)
Affinity DataEC50:  60nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509630(N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromet...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509725(N-(4-tert-Butylcyclohexyl)-4-[[2-(5-chloro-2-hydro...)
Affinity DataEC50:  60nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509226(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509630(N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromet...)
Affinity DataEC50:  60nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509579(US11364246, Example 3.3a | US20200361871A1, Exampl...)
Affinity DataEC50:  70nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509777(US11364246, Example 93.4 | US20200361871A1, Exampl...)
Affinity DataEC50:  70nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509579(US11364246, Example 3.3a | US20200361871A1, Exampl...)
Affinity DataEC50:  70nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509777(US11364246, Example 93.4 | US20200361871A1, Exampl...)
Affinity DataEC50:  70nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509231(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-c...)
Affinity DataEC50:  80nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509231(4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-c...)
Affinity DataEC50:  80nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509647(US11364246, Example 7.13 | US20200361871A1, Exampl...)
Affinity DataEC50:  90nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetAnoctamin-1(Homo sapiens (Human))
Enterprise Therapeutics

US Patent
LigandPNGBDBM509769(N-tert-Butyl-4-[[2-(4-tert-butyl-3-hydroxy-phenyl)...)
Affinity DataEC50:  90nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 466 total ) | Next | Last >>
Jump to: